PJSC Mechel
16.7.2021 11:22:01 CEST | ACCESS Newswire | Press release
MOSCOW, RUSSIA / ACCESSWIRE / July 16, 2021 / Mechel PAO (NYSE: MTL, MOEX: MTLR), a leading Russian mining and metals company, reports discharging all obligations regarding the company's public debt.
Mechel reports that the company has fully repaid its 04 series bonds as earlier scheduled. The company has thus completed discharging all obligations it assumed regarding bond series restructured in 2015-2016.
In 2015-2016, bondholders approved restructuring of obligations on bonds of the 04, 13, 14, 17, 18 and 19 series with nominal value totaling 30 billion rubles, renouncing the right to demand advance redemption. The repaid coupon yield for these series totaled 24.9 billion rubles with interest rates of 8% to 19%.
"We have completely fulfilled all of our public debt obligations and are grateful to Mechel PAO's bondholders who reached out to us in our time of need and agreed to restructuring terms that were acceptable to the company," Mechel PAO's Chief Executive Officer Oleg Korzhov commented..
***
Mechel PAO
Ekaterina Videman
Tel: + 7 495 221 88 88
***
Mechel is an international mining and steel company. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.
***
Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of Mechel, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We wish to caution you that these statements are only predictions and that actual events or results may differ materially. We do not intend to update these statements. We refer you to the documents Mechel files from time to time with the U.S. Securities and Exchange Commission, including our Form 20-F. These documents contain and identify important factors, including those contained in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in our Form 20-F, that could cause the actual results to differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, volatility in stock markets or in the price of our shares or ADRs, financial risk management and the impact of general business and global economic conditions.
SOURCE: PJSC Mechel
View source version on accesswire.com:
https://www.accesswire.com/655810/PJSC-Mechel-Mechel-Reports-Redemption-of-Corporate-Bonds
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Announces Second Tranche Investment of $800,000 in Solaris Energy's U.S. Distributed Generation Solar Portfolio9.2.2026 23:00:00 CET | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / February 9, 2026 / RE Royalties Ltd. (TSX.V:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further USD $800,000 investment toward the purchase of royalties on two portfolios of distributed generation ("DG") solar projects located throughout the United States being developed by Solaris Energy Inc. ("Solaris"). The Royalty Purchase for Portfolio 1 totals USD $4.8 million, of which USD $3 million was funded at closing, as announced on January 7, 2026. The Company expects to fund the remaining USD $1 million by Q2 2026, subject to the satisfaction of applicable conditions. The Royalty Purchase for Portfolio 2 is subject to the completion of due diligence to the satisfaction of the Company, other customary closing conditions, and is expected to occur later in the year, bringing the total portfolio level royalty investment to USD $9 million. The Royalty Rate will be adju
UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities9.2.2026 06:00:00 CET | Press release
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In addition, Vesalic has discovered a disease-specific alteration of the lipid composition in the membranes of exosomes circulating in the blood, and has developed a highly accurate biomarker-based technology to detect both monogenic and sporadic ALS Based on its novel biomarker discoveries, Vesalic is also applying its biomarker technology for other neurodegenerative diseases, including Alzheimer's and Parkinson's LONDON, UK / ACCESS Newswire / February 9, 2026 / Vesalic Limited, an early-stage neurodegenerative disease-focused biotech company, today emerged from stealth with the landmark discovery of a systemic process - largely
Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
